Hafezi, Farhad http://orcid.org/0000-0001-8935-4558
Hosny, Mohammed
Shetty, Rohit
Knyazer, Boris
Chen, Shihao
Wang, Qinmei
Hashemi, Hassan
Torres-Netto, Emilio A.
Zhang, Hanxiao
Bora’i, Ashraf
Tawfeek, Mohamed
Nagaraja, Harsha
D’Souza, Sharon
Asgari, Soheila
Mirsalim, Agha
Chorny, Alexander
Krakauer, Yonit
Pajic, Bojan
Gilardoni, Francesca
Hafezi, Nikki
Hillen, Mark
Liu, Nanji
Boldi, Marc-Olivier
Tabibian, David
Torgerson, Paul R.
Zbinden, Reinhard
Koliwer-Brandl, Hendrik
Bradley Randleman, J.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
PACK-CXL vs. antimicrobial therapy for bacterial, fungal, and mixed infectious keratitis: a prospective randomized phase 3 trial
https://doi.org/10.1186/s40662-021-00272-0
Funding for this research was provided by:
Light for Sight Foundation, Zurich, Switzerland
Article History
Received: 16 June 2021
Accepted: 27 November 2021
First Online: 7 January 2022
Declarations
:
: The Institutional Review Boards of all study sites involved prospectively approved the study protocol, which adhered to all local laws and the tenets of the Declaration of Helsinki, and written informed consent was obtained by all participants before inclusion.
: Not applicable.
: Farhad Hafezi is the chief scientific officer of EMAGine AG (Zug, Switzerland), co-inventor of the PCT applications CH2012/0000090 and PCT2014/CH000075 regarding CXL technology, and an editorial board member of the journal. The other authors have no competing interest in the materials presented herein.